(Q34519151)

2 August 2017

1 reference

title

Antihistamines in late-phase clinical development for allergic disease (English)

1 reference

2 August 2017

1 reference

Luis M Salmun

1

1 reference

PubMed ID

11829715

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

11

1 reference

2 August 2017

2

1 reference

2 August 2017

259-273

1 reference

National guidelines needed to manage rhinitis and prevent complications

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Comparative tolerability of second generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Immunologic basis of antigen-induced airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Allergy and allergic diseases. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Augmentation by eosinophils of gelatinase activity in the airway mucosa: comparative effects as a putative mediator of epithelial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

New insights into the second generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Evaluation and management of allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Clinical pharmacokinetics of mizolastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

A new model of allergic rhinitis in rats by topical sensitization and evaluation of H(1)-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Ebastine: an update of its use in allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Clinical pharmacology of new histamine H1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.259

10.1517/13543784.11.2.259

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11829715